Samuele Renzi1, Orli Michaeli1, Vijay Ramaswamy1, Annie Huang1, Derek Stephens2, Bryan Maguire2, Uri Tabori1, Eric Bouffet1, Ute Bartels3. 1. Division of Hematology/Oncology, the Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 2M9, Canada. 2. Division of Statistics, the Hospital for Sick Children, Toronto, Canada. 3. Division of Hematology/Oncology, the Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 2M9, Canada. ute.bartels@sickkids.ca.
Abstract
PURPOSE: Primary benign and malignant central nervous system (CNS) tumors are the most frequent solid tumors in the pediatric age and represent the leading cause of death by cancer in children in high income countries. However, information regarding specific causes of death in this population is still limited. The objective of this work was to investigate mortality in a large cohort of children diagnosed at our institution. METHODS: We identified patients consecutively diagnosed with CNS tumor and treated at a Tertiary Care Canadian Children's Hospital between January 2000 and December 2017. Patient charts were reviewed and different variables such as tumor diagnosis, location, gender, age at diagnosis, age at death and cause of death collected. RESULTS: Of 1274 patients, 306 (24%) succumbed to their disease. Mortality rate varied significantly according to tumor subtype, ranging from 3.1% in low grade glioma (LGG) to 97.8% in diffuse intrinsic pontine glioma (DIPG). While high grade gliomas (HGG) and DIPG represented only 6.3 and 7.1% of total diagnoses respectively, together they accounted for 49.3% of total deaths (n = 151). Median time from diagnosis to death was 15 months (4 days to 15 years) and shortest for DIPG (11 months). Two hundred and ninety patients (94.8%) died as a result of the primary disease, 4 of treatment-related toxicity, two patients' deaths were unrelated to the primary disease (idiopathic encephalopathy and domestic fire) whereas 10 patients succumbed to a secondary malignancy. Of note, four of these ten patients had a confirmed underlying cancer predisposition syndrome. CONCLUSION: Disease progression is the main cause of death in children with brain tumor, while treatment related mortality is low in this series. Research should continue to focus on improving treatment strategies for patients whose prognosis remains dismal.
PURPOSE: Primary benign and malignant central nervous system (CNS) tumors are the most frequent solid tumors in the pediatric age and represent the leading cause of death by cancer in children in high income countries. However, information regarding specific causes of death in this population is still limited. The objective of this work was to investigate mortality in a large cohort of children diagnosed at our institution. METHODS: We identified patients consecutively diagnosed with CNS tumor and treated at a Tertiary Care Canadian Children's Hospital between January 2000 and December 2017. Patient charts were reviewed and different variables such as tumor diagnosis, location, gender, age at diagnosis, age at death and cause of death collected. RESULTS: Of 1274 patients, 306 (24%) succumbed to their disease. Mortality rate varied significantly according to tumor subtype, ranging from 3.1% in low grade glioma (LGG) to 97.8% in diffuse intrinsic pontine glioma (DIPG). While high grade gliomas (HGG) and DIPG represented only 6.3 and 7.1% of total diagnoses respectively, together they accounted for 49.3% of total deaths (n = 151). Median time from diagnosis to death was 15 months (4 days to 15 years) and shortest for DIPG (11 months). Two hundred and ninety patients (94.8%) died as a result of the primary disease, 4 of treatment-related toxicity, two patients' deaths were unrelated to the primary disease (idiopathic encephalopathy and domestic fire) whereas 10 patients succumbed to a secondary malignancy. Of note, four of these ten patients had a confirmed underlying cancer predisposition syndrome. CONCLUSION: Disease progression is the main cause of death in children with brain tumor, while treatment related mortality is low in this series. Research should continue to focus on improving treatment strategies for patients whose prognosis remains dismal.
Entities:
Keywords:
Brain tumors; CNS; Central nervous system tumors; Mortality; Pediatric
Authors: Adelheid Wöhrer; Thomas Waldhör; Harald Heinzl; Monika Hackl; Johann Feichtinger; Ulrike Gruber-Mösenbacher; Andreas Kiefer; Hans Maier; Reinhard Motz; Angelika Reiner-Concin; Bernd Richling; Carmen Idriceanu; Michael Scarpatetti; Roland Sedivy; Hans-Christian Bankl; Wolfgang Stiglbauer; Matthias Preusser; Karl Rössler; Johannes Andreas Hainfellner Journal: J Neurooncol Date: 2009-06-28 Impact factor: 4.130
Authors: Tabitha Cooney; Adam Lane; Ute Bartels; Eric Bouffet; Stewart Goldman; Sarah E S Leary; Nicholas K Foreman; Roger J Packer; Alberto Broniscer; Jane E Minturn; Chie-Schin Shih; Murali Chintagumpala; Tim Hassall; Nicholas G Gottardo; Hetal Dholaria; Lindsey Hoffman; Brooklyn Chaney; Joshua Baugh; Renee Doughman; James L Leach; Blaise V Jones; Maryam Fouladi; Katherine E Warren; Michelle Monje Journal: Neuro Oncol Date: 2017-09-01 Impact factor: 12.300
Authors: Amar Gajjar; Daniel C Bowers; Matthias A Karajannis; Sarah Leary; Hendrik Witt; Nicholas G Gottardo Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Vladimír Beneš; Michal Zápotocký; Petr Libý; Jakub Táborský; Jana Blažková; Jana Blažková; David Sumerauer; Adéla Mišove; Ivana Perníková; Martin Kynčl; Lenka Krsková; Miroslav Koblížek; Josef Zámečník; Ondřej Bradáč; Michal Tichý Journal: Acta Neurochir (Wien) Date: 2022-01-19 Impact factor: 2.216
Authors: Sarah Metzger; Annette Weiser; Nicolas U Gerber; Maria Otth; Katrin Scheinemann; Niklaus Krayenbühl; Michael A Grotzer; Ana S Guerreiro Stucklin Journal: J Neurooncol Date: 2022-02-11 Impact factor: 4.506